Advancements in Tenosynovial Giant Cell Tumor Treatment with Surgery and Targeted Therapies

Tenosynovial giant cell tumor, also known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS), is primarily treate...

March 05, 2025 | Wednesday | News
Axplora Expands ADC Manufacturing Leadership with New Payload Facility in France

Axplora, a global leader in API small molecule and ADC (antibody-drug conjugate) manufacturing, is strengthening its leading position in the commercial m...

March 04, 2025 | Tuesday | News
Callio Therapeutics Launches with $187M Series A for ADC Cancer Therapy

Callio Therapeutics, a biotechnology company focused on realizing the promise of multi-payload antibody-drug conjugates (ADCs) to improve cancer therapy, a...

March 04, 2025 | Tuesday | News
Myosin Therapeutics Secures Funding to Advance MT-125 for Glioblastoma, MT-110 for Addiction

 Myosin Therapeutics, Inc., a biotechnology company developing novel therapies for cancer and neurological disorders, has closed its second seed fundi...

March 04, 2025 | Tuesday | News
CStone Begins Phase I Trial of CS2009 Trispecific Antibody for Solid Tumors

CStone Pharmaceuticals, an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced that&nbs...

March 04, 2025 | Tuesday | News
Myriad Genetics Partners with Gabbi to Enhance Breast Cancer Risk Assessment and Specialist Care

Myriad Genetics, Inc., a leader in molecular diagnostics testing and precision medicine, announced a collaboration with Gabbi, a telehealth solution f...

February 28, 2025 | Friday | News
Medigene and EpimAb Partner to Advance Off-the-Shelf TCR-TCE Therapies for Cancer

Medigene AG and EpimAb Biotherapeutics, Inc. (EpimAb), announced that the companies have entered a strategic co-development agreement to research and dev...

February 27, 2025 | Thursday | News
Renovaro Biosciences and BioSymetrics Merge to Advance AI-Driven Precision Medicine

Strategic Combination Aims to Accelerate Biomarker Identification, Enhance Drug Discovery, and Expand Precision Medicine Applications in Cancer and Beyon...

February 27, 2025 | Thursday | News
Novita Pharmaceuticals Unveils Promising Phase 2 Results for NP-G2-044 in Combination with Anti-PD-1 Therapy at AACR IO Annual Meeting

 Novita Pharmaceuticals, Inc. ("Novita"), a privately held, clinical-stage pharmaceutical company dedicated to developing novel cancer drugs through i...

February 26, 2025 | Wednesday | News
Telix Pharmaceuticals Announces FDA Acceptance of Biologics License Application for Breakthrough Kidney Cancer Imaging Agent TLX250-CDx

Telix Pharmaceuticals Limited  announces that the United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License...

February 26, 2025 | Wednesday | News
Akeso Partner Summit Therapeutics Collaborates with Pfizer to Evaluate Ivonescimab in Combination with Pfizer’s ADCs in Solid Tumors

Akeso, Inc. ("Akeso" or the "Company") announced that its partner on ivonescimab, Summit Therapeutics Inc.  has entered into a clinical trial collabor...

February 25, 2025 | Tuesday | News
Bristol Myers Squibb Announces FDA Acceptance of sBLA for Opdivo® Plus Yervoy® as First-Line Treatment for MSI-H or dMMR Metastatic Colorectal Cancer

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application (sBLA) for...

February 25, 2025 | Tuesday | News
Bristol Myers Squibb Announces Positive Final Overall Survival Data for Opdivo® in Resectable NSCLC

Bristol Myers Squibb announced the final analysis of overall survival (OS) from the Phase 3 CheckMate -816 study, which evaluated Opdivo (ni...

February 21, 2025 | Friday | News
Genprex Advances Diabetes Program with Strategic Collaboration to Explore Non-Viral Gene Therapy Delivery System

Genprex, Inc., a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, announced the adv...

February 20, 2025 | Thursday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close